Global Leukemia Therapeutics Market 2016-2020

  • Published: Sep 2016
  • Pages: 110
  • SKU: IRTNTR10286

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

This market research study analyzes the key players in the leukemia therapeutics market such as F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, and Teva Pharmaceuticals. This report also presents a competitive analysis of the market by disease (CML, CLL, AML, and ALL) and by geography (the Americas, APAC, and EMEA).

Global leukemia therapeutics market forecasts

According to the leukemia therapeutics industry insights at Technavio, the leukemia therapeutics market will witness fast-paced growth and will post a staggering CAGR of more than 8% over the forecast period. The application for expanded indication approvals is one of the primary factors driving the growth of this market. The concept of repositioning came into practice in the early 1990s and is based on the possibility that different diseases could be sharing common molecular pathways. This has led several companies to conduct clinical trials to determine the effectiveness of the drugs in all such related indications. As this process of drug re-positioning leading to extended indication is a low-risk, high-reward strategy, it could increase the scope of treatment and help in increased market penetration.

One of the recent leukemia therapeutics market trends propelling the growth prospects for this market is the rise in the development of combination therapies to treat leukemia. Combination therapies for the treatment of leukemia are mostly available in the form of combination chemotherapy drugs. Some of the approved combinations include chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of chronic lymphocytic leukemia (CLL); a combination of cytarabine, daunorubicin, and etoposide for the treatment of acute myeloid leukemia (AML); and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of acute lymphocytic leukemia (ALL). These therapies are expected to increase the effectiveness of the treatment, which in turn, will increase the patient compliance toward the use of these drugs.

Competitive landscape and key vendors

The leukemia therapeutics market characterized by the presence of several well-established vendors. The market is growing steadily because of an augmented demand for leukemia drugs, which is also expected to boost R&D activities. The vendors are manufacturing and selling drugs that can effectively treat the disease, and also possess a high efficacy and safety profile. This is expected to help the vendors to gain a competitive edge over their peers.

 Key vendors in this market are 

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals

Other prominent vendors in the market include Altor BioScience, Ambit BioSciences, Amgen, Ariad Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene Corporation, CTI Biopharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme Corp, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, Meda, MedImmune, Merck, Midas Pharmaceuticals, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.

Segmentation by disease type and analysis of the leukemia therapeutics market  

  • ALL
  • CML
  • CLL
  • AML

The global CML therapeutics segment is one of the fastest growing segments of the market and is expected to reach over USD 5 billion by 2020. Factors such as the increasing use of combination therapies and the introduction of several breakthrough drugs in the market will drive this segment’s growth in the coming years.

Geographical segmentation and analysis of the leukemia therapeutics market 

  • Americas
  • APAC
  • EMEA

In terms of geography, the Americas led the leukemia therapeutics market and is anticipated to reach close to USD 7 billion in 2020. The US is the largest revenue contributor in the region. The growth of this market in the region is attributed to the high prevalence of the disease in the region. According to several research studies, nearly 61,000 new cases of leukemia will be diagnosed in the US in 2016, of which 20,000 cases will be of AML. Furthermore, the presence of patient assistance programs by government and non-government organizations in the US are also expected to drive market growth. As drugs such as Iclusig, Rituxan, and Arzerra are costly, patient withdrawal from the treatment regimen is common. Instead, end-users prefer affordable generic medication such as generic imatinib. However, the availability of patient assistance programs from vendors and other government and non-government organizations will help decrease non-compliance among individuals and increase the demand for branded TKIs.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the leukemia therapeutics market?
  • What are the key market trends impacting the growth of the leukemia therapeutics market?
  • What are the challenges to market growth?
  • Who are the key vendors in the leukemia therapeutics market?
  • What are the market opportunities and threats faced by the vendors in the leukemia therapeutics market?
  • What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
  • What are the key outcomes of the five forces analysis of the leukemia therapeutics market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:


Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by disease type

PART 08: Global CLL therapeutics market

  • Market overview
  • Total addressable market for global CLL therapeutics
  • Vendors in the market

PART 09: Global ALL therapeutics market

  • Market overview
  • Vendors in the market

PART 10: Global AML therapeutics market

  • Market overview
  • Vendors in the market

PART 11: Global CML therapeutics market

  • Market overview
  • Vendors in the market

PART 12: Geographical segmentation

  • Global leukemia therapeutics market by geography 2015-2020
  • Leukemia therapeutics market in Americas
  • Leukemia therapeutics market in EMEA
  • Leukemia therapeutics market in APAC

PART 13: Market drivers

  • Special regulatory designations for drugs
  • Technological advances in the monitoring of leukemia
  • Application for expanded indication approvals

PART 14: Impact of drivers

PART 15: Market challenges

  • Complicated disease prognosis
  • Financial and infrastructural constraints
  • Limitations associated with current therapeutic options
  • Delay in diagnosis

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Rise in the development of combination therapies
  • Patient assistance programs
  • Focus on the identification of targets for the development of new therapies

PART 18: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 19: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novartis
  • Bristol-Myers Squibb
  • AbbVie
  • Teva Pharmaceuticals

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted

  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>